- Home
- WTI vs NMRA Comparison
WTI vs NMRA Comparison
Compare WTI & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTI
- NMRA
- Stock Information
- Founded
- WTI 1983
- NMRA 2019
- Country
- WTI United States
- NMRA United States
- Employees
- WTI N/A
- NMRA N/A
- Industry
- WTI Oil & Gas Production
- NMRA
- Sector
- WTI Energy
- NMRA
- Exchange
- WTI Nasdaq
- NMRA Nasdaq
- Market Cap
- WTI 332.3M
- NMRA 291.5M
- IPO Year
- WTI 2005
- NMRA 2023
- Fundamental
- Price
- WTI $2.15
- NMRA $2.49
- Analyst Decision
- WTI
- NMRA Buy
- Analyst Count
- WTI 0
- NMRA 8
- Target Price
- WTI N/A
- NMRA $7.43
- AVG Volume (30 Days)
- WTI 2.6M
- NMRA 2.3M
- Earning Date
- WTI 11-05-2025
- NMRA 11-06-2025
- Dividend Yield
- WTI 1.88%
- NMRA N/A
- EPS Growth
- WTI N/A
- NMRA N/A
- EPS
- WTI N/A
- NMRA N/A
- Revenue
- WTI $493,951,000.00
- NMRA N/A
- Revenue This Year
- WTI $7.18
- NMRA N/A
- Revenue Next Year
- WTI $5.71
- NMRA N/A
- P/E Ratio
- WTI N/A
- NMRA N/A
- Revenue Growth
- WTI N/A
- NMRA N/A
- 52 Week Low
- WTI $1.09
- NMRA $0.61
- 52 Week High
- WTI $2.59
- NMRA $14.09
- Technical
- Relative Strength Index (RSI)
- WTI 52.36
- NMRA 68.71
- Support Level
- WTI $2.05
- NMRA $1.68
- Resistance Level
- WTI $2.34
- NMRA $2.72
- Average True Range (ATR)
- WTI 0.15
- NMRA 0.20
- MACD
- WTI -0.02
- NMRA 0.08
- Stochastic Oscillator
- WTI 22.24
- NMRA 81.89
About WTI W&T Offshore Inc.
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.